Please ensure Javascript is enabled for purposes of website accessibility

Why DermTech Stock Jumped Today

By Jeremy Bowman - Updated Feb 11, 2021 at 1:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the skin-cancer genomics company gained as it opened up a new customer base.

What happened

Shares of DermTech (DMTK -0.95%) were moving higher today after the biotech announced an agreement with Blue Cross Blue Shield of Texas (BCBSTX) to make the company's Pigmented Legion Assay (PLA) available to the insurer's approximately 6 million members in that state.  

The stock was up 23.6% as of 12:13 p.m. EST on Thursday as a result.

A DermTech PLA patch

The DermTech PLA patch. Image source: DermTech.

So what

DermTech's PLA allows for easy testing of melanomas, and the technology can help increase early detection of skin cancer. Recent tests have shown that the PLA patch has a negative predictive value of 99%, meaning there's less than a 1% chance of missing a melanoma when used properly.

Momentum has been building for the PLA in recent months, and opening the market to 6 million more people is a big step forward.

Dan Visage, DermTech's senior vice president for payor access, said: "We are happy to announce our test as an in-network option for our current users of the PLA. This agreement with BCBSTX shows DermTech's commitment to making its transformative PLA test accessible to more patients."

Now what

Shares of DermTech have now doubled this year and are up more than 400% since early December as excitement is building for the PLA. The stock has surged as the company has announced positive results from testing, raised money for the PLA's commercialization and for research into new products, and received a number of analyst upgrades. This morning, Lake Street raised its price target on DermTech stock from $52 to $79, and maintained its buy rating.

The company sees an addressable market of close to $10 billion for the technology, indicating a long runway for growth. Considering that the healthcare stock is still valued at less than $2 billion, it should have more upside from here if it can penetrate that market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DermTech, Inc. Stock Quote
DermTech, Inc.
$7.30 (-0.95%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.